Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment

Epstein-Barr virus (EBV) is a pathogen that infects more than 90% of global human population. EBV primarily targets Blymphocytes and epithelial cells while some of them infect monocyte/macrophage, T-lymphocytes, and dendritic cells (DCs). EBV infection does not cause death by itself but the infectio...

Full description

Bibliographic Details
Main Authors: Teow, Sin Yeang *, Yap, Hooi Yeen *, Peh, Suat Cheng *
Format: Article
Language:English
Published: Hindawi Publishing 2017
Subjects:
Online Access:http://eprints.sunway.edu.my/831/
http://eprints.sunway.edu.my/831/1/Ronald%20Teow%20Epstein%20Barr%20virus.pdf
_version_ 1848801905955831808
author Teow, Sin Yeang *
Yap, Hooi Yeen *
Peh, Suat Cheng *
author_facet Teow, Sin Yeang *
Yap, Hooi Yeen *
Peh, Suat Cheng *
author_sort Teow, Sin Yeang *
building SU Institutional Repository
collection Online Access
description Epstein-Barr virus (EBV) is a pathogen that infects more than 90% of global human population. EBV primarily targets Blymphocytes and epithelial cells while some of them infect monocyte/macrophage, T-lymphocytes, and dendritic cells (DCs). EBV infection does not cause death by itself but the infection has been persistently associated with certain type of cancers such as nasopharyngeal carcinoma (NPC), Burkitt’s lymphoma (BL), and Hodgkin’s lymphoma (HL). Recent findings have shown promise on targeting EBV proteins for cancer therapy by immunotherapeutic approach. Some studies have also shown the success of adopting EBV-based therapeutic vaccines for the prevention of EBV-associated cancer particularly on NPC. In-depth investigations are in progress to refine the current therapeutic and vaccination strategies. In present review, we discuss the highly potential EBV targets for NPC immunotherapy and therapeutic vaccine development aswell as addressing the underlying challenges in the process of bringing the therapy and vaccination from the bench to bedside.
first_indexed 2025-11-14T21:14:53Z
format Article
id sunway-831
institution Sunway University
institution_category Local University
language English
last_indexed 2025-11-14T21:14:53Z
publishDate 2017
publisher Hindawi Publishing
recordtype eprints
repository_type Digital Repository
spelling sunway-8312019-04-30T08:24:09Z http://eprints.sunway.edu.my/831/ Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment Teow, Sin Yeang * Yap, Hooi Yeen * Peh, Suat Cheng * RC0254 Neoplasms. Tumors. Oncology (including Cancer) Epstein-Barr virus (EBV) is a pathogen that infects more than 90% of global human population. EBV primarily targets Blymphocytes and epithelial cells while some of them infect monocyte/macrophage, T-lymphocytes, and dendritic cells (DCs). EBV infection does not cause death by itself but the infection has been persistently associated with certain type of cancers such as nasopharyngeal carcinoma (NPC), Burkitt’s lymphoma (BL), and Hodgkin’s lymphoma (HL). Recent findings have shown promise on targeting EBV proteins for cancer therapy by immunotherapeutic approach. Some studies have also shown the success of adopting EBV-based therapeutic vaccines for the prevention of EBV-associated cancer particularly on NPC. In-depth investigations are in progress to refine the current therapeutic and vaccination strategies. In present review, we discuss the highly potential EBV targets for NPC immunotherapy and therapeutic vaccine development aswell as addressing the underlying challenges in the process of bringing the therapy and vaccination from the bench to bedside. Hindawi Publishing 2017-12-31 Article PeerReviewed text en cc_by_4 http://eprints.sunway.edu.my/831/1/Ronald%20Teow%20Epstein%20Barr%20virus.pdf Teow, Sin Yeang * and Yap, Hooi Yeen * and Peh, Suat Cheng * (2017) Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment. Journal of Pathogens. pp. 1-10. ISSN 2090-3057 http://doi.org/10.1155/2017/7349268 doi:10.1155/2017/7349268
spellingShingle RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Teow, Sin Yeang *
Yap, Hooi Yeen *
Peh, Suat Cheng *
Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment
title Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment
title_full Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment
title_fullStr Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment
title_full_unstemmed Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment
title_short Epstein-Barr Virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment
title_sort epstein-barr virus as a promising immunotherapeutic target for nasopharyngeal carcinoma treatment
topic RC0254 Neoplasms. Tumors. Oncology (including Cancer)
url http://eprints.sunway.edu.my/831/
http://eprints.sunway.edu.my/831/
http://eprints.sunway.edu.my/831/
http://eprints.sunway.edu.my/831/1/Ronald%20Teow%20Epstein%20Barr%20virus.pdf